New Pharmaceuticals market report from Global Markets Direct: "Asthma - Pipeline Review, H2 2013"
Boston, MA -- (SBWIRE) -- 09/27/2013 -- Global Markets Direct's, 'Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
View Full Report Details and Table of Contents
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Asthma.
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Asthma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to Get This Report
- Identify and understand important and diverse types of therapeutics under development for Asthma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Alcon, Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., EpiGenesis Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline plc, Genentech, Inc., Biotec Pharmacon ASA, MedImmune LLC, Daiichi Sankyo Company, Ltd, Merck & Co., Inc., Nissan Chemical Industries, Ltd., Ablynx, Dainippon Sumitomo Pharma Co., Ltd., Infinity Pharmaceuticals, Inc., SkyePharma PLC, Vectura Group plc, BioLineRx, Ltd., Novartis AG, Isotechnika Pharma Inc., Actelion Ltd, ALK-Abello A/S, ASKA Pharmaceutical Co., Ltd, Astellas Pharma Inc., Chiesi Farmaceutici SpA, Dong-A Pharmaceutical Co., Ltd., Glenmark Pharmaceuticals Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Orion Corporation, Pfizer Inc., Rigel Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Zambon Group S.p.A., Sun Pharmaceutical Industries Limited, OPKO Health, Inc., iCo Therapeutics Inc., Antisense Therapeutics Limited, Idera Pharmaceuticals, Inc., Almirall, S.A., Basilea Pharmaceutica Ltd., Mesoblast Ltd, Orchid Chemicals & Pharmaceuticals Ltd, Palatin Technologies, Inc., Pharmaxis Ltd., Portola Pharmaceuticals, Inc., CSL Limited, Cytokinetics, Inc, Yungjin Pharm Ind. Co., Ltd., Yuhan Corporation, WhanIn Pharmaceutical Co., Ltd., Regeneron Pharmaceuticals, Inc., NeoStem, Inc., Array BioPharma Inc., Dynavax Technologies Corporation, Stallergenes S.A., Cytos Biotechnology AG, Ahn-Gook Pharmaceutical Co., Ltd., HYUNDAI PHARM. CO., LTD., Neurim Pharmaceuticals (1991) Ltd., Synairgen plc, Panacea Biotec Limited, Orexo AB, Verona Pharma Plc, Morphotek, Inc., Marinomed Biotechnologie GmbH, Alba Therapeutics Corporation, Allergopharma Joachim Ganzer KG, Immupharma Plc, Palau Pharma S.A, Farmacija d.o.o. Tuzla, Pieris AG, Respiratorius AB, Aquinox Pharmaceuticals Inc., Proteologics, Inc., Funxional Therapeutics Ltd, ZaBeCor Pharmaceuticals, Nostrum Pharmaceuticals, LLC, Promedior, Inc., Pulmatrix, Inc., Axikin Pharmaceuticals, Inc., Five Prime Therapeutics, Inc., MSM Protein Technologies, Inc., Indus Biotech Private Limited, AIM Therapeutics Inc., Hydra Biosciences, Inc., Theraclone Sciences, Inc., Vantia Therapeutics, Biotica Technology Ltd, Monosol Rx, LLC, NKT Therapeutics, Inc., Omeros Corporation, Transtech Pharma, Inc., Xencor, Inc., Cornerstone Therapeutics Inc., Targacept, Inc., BaroFold, Inc., Cellceutix Corporation, CBio Limited, KaloBios Pharmaceuticals, Inc., AB Science, Adamis Pharmaceuticals Corporation, Asmacure Limited, Lycera Corp., ISU ABXIS Co.,Ltd., KAEL-GemVax, iCeutica, Inc., N30 Pharmaceuticals, GlycoMar Limited, Biocure pharm, Clarassance, Inc.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Melanoma - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013
- Prostate Cancer - Pipeline Review, H2 2013
- Stroke - Pipeline Review, H2 2013
- Type 2 Diabetes - Pipeline Review, H2 2013
- Crohn's Disease - Pipeline Review, H2 2013
- Macular Degeneration - Pipeline Review, H2 2013
- Kidney Disease - Pipeline Review, H2 2013
- Schizophrenia - Pipeline Review, H2 2013